In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses the application of MRD in colorectal and breast cancer, highlighting its ability to predict early recurrence before radiologic signs appear, as evidenced in various trials. He emphasizes the sensitivity of MRD testing in detecting early recurrence.
Dr. Mchayleh advocates for a proactive approach to using MRD in the neoadjuvant setting for early breast cancer. He envisions a shift where MRD not only predicts treatment responses but also influences therapeutic strategies based on MRD outcomes, particularly gauging the clearance of plasma during treatment.
Expressing interest in further exploration, Dr. Mchayleh calls for expanded clinical trials incorporating Circulating Tumor DNA (CTDNA) alongside MRD. He envisions a future where these tools become integral, allowing for early interventions and personalized treatment adjustments. Dr. Mchayleh underscores the underutilization of CTDNA, urging its inclusion in clinical trials to potentially enhance breast cancer treatment approaches and outcomes.